About: Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $20.59 (-7.38%)
MLYS NASDAQ Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc. Common Stock share price
MLYS price activity
Last Price
$20.590
Change (24hr)
-1.64 USD (-7.38%)
Volume
2.15M
Volume (4w avg)
-
Open
$22.04
Day Range
$20.59 - $22.04
Previous Close
$22.23
Last Trade
13 Oct, 6:34 pm GMT+0
Delayed
13 Oct, 6:34 pm GMT+0
MLYS price performance
Delayed
13 Oct, 6:34 pm GMT+0
MLYS Market Signals